🇺🇸 FDA
Pipeline program

2mg INO-5150 and electroporation device CELLECTRA®-5P

PCa-001

Phase 1 mab completed

Quick answer

2mg INO-5150 and electroporation device CELLECTRA®-5P for Prostate Cancer is a Phase 1 program (mab) at INOVIO PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
INOVIO PHARMACEUTICALS, INC.
Indication
Prostate Cancer
Phase
Phase 1
Modality
mab
Status
completed

Clinical trials